In this issue:
177Lu-PSMA-617 in mCRPC: ctDNA analysis
Statin use in advanced prostate cancer
Metastases-directed therapy in oligometastatic CRPC
Baseline PSMA-PET biomarkers in mCRPC
Enzalutamide + radium-223 for mCRPC
Circulating lipids and clinical outcomes in mHSPC
Severe late toxicity after hypofractionated post-prostatectomy radiotherapy
Prostate stereotactic ablative body radiotherapy every other day or once a week
Years of life lost in metastatic and locally advanced prostate cancer
Adjuvant docetaxel for prostate cancer after radical curative radiotherapy
Please login below to download this issue (PDF)